This company has been acquired
Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
BLU Aktienübersicht
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BELLUS Health Inc. Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | CA$19.50 |
| 52 Week High | CA$19.90 |
| 52 Week Low | CA$8.58 |
| Beta | -0.28 |
| 1 Month Change | -1.42% |
| 3 Month Change | 100.82% |
| 1 Year Change | 50.70% |
| 3 Year Change | 38.79% |
| 5 Year Change | 962.09% |
| Change since IPO | -97.95% |
Aktuelle Nachrichten und Updates
Recent updates
BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans
Jan 16
Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation
Sep 07We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely
May 05Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation
Jan 06Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth
Sep 10Aktionärsrenditen
| BLU | CA Biotechs | CA Markt | |
|---|---|---|---|
| 7D | 0.5% | -6.8% | -1.4% |
| 1Y | 50.7% | -29.7% | 10.8% |
Rendite im Vergleich zur Industrie: BLU exceeded the Canadian Biotechs industry which returned 23.5% over the past year.
Rendite vs. Markt: BLU exceeded the Canadian Market which returned 0.8% over the past year.
Preisvolatilität
| BLU volatility | |
|---|---|
| BLU Average Weekly Movement | 28.1% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 17.0% |
| 10% least volatile stocks in CA Market | 3.0% |
Stabiler Aktienkurs: BLU's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: BLU's weekly volatility has increased from 16% to 28% over the past year.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1993 | 74 | Roberto Bellini | www.bellushealth.com |
BELLUS Health Inc.'s Grundlagenzusammenfassung
| BLU grundlegende Statistiken | |
|---|---|
| Marktanteil | CA$2.47b |
| Gewinn(TTM) | -CA$115.02m |
| Umsatz(TTM) | CA$19.88k |
Over9,999x
Kurs-Umsatz-Verhältnis-21.5x
Kurs-Gewinn-VerhältnisIst BLU zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| BLU Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$15.00k |
| Kosten der Einnahmen | US$0 |
| Bruttogewinn | US$15.00k |
| Sonstige Ausgaben | US$86.80m |
| Umsatz | -US$86.79m |
Zuletzt gemeldete Gewinne
Mar 31, 2023
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.68 |
| Bruttomarge | 100.00% |
| Nettogewinnspanne | -578,586.67% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich BLU auf lange Sicht entwickelt?
Historische Performance und Vergleiche